Trial Profile
A Single Center Open Label Pilot Study of Alpha1-Antitrypsin: A Novel Treatment to Mitigate Neuromyelitis Optica Attacks
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Alpha 1-antitrypsin (Primary) ; Methylprednisolone
- Indications Neuromyelitis optica
- Focus Therapeutic Use
- 10 Apr 2019 Status changed from recruiting to withdrawn prior to enrolment.
- 17 May 2018 New trial record